Hands-on Clinically Applied Ketobolomics & Deuterobolomics Post-Conference Workshop (non-CME) Sunday, September 17: 8AM - 12PM
$399 ACAM Member & Non-member
ABOUT THE WORKSHOP: The U.S. Food and Drug Administration in April of 2017 allowed marketing of 23andMe Personal Genome Service Genetic Health Risk (GHR) tests for 10 diseases or conditions. Although these are the first direct-to-consumer (DTC) tests authorized by the FDA that provide information on an individual’s genetic predisposition to a few medical diseases or conditions, the FDA is very specific about the fact that results obtained from genetic tests should not be used for diagnosis or to inform treatment decisions. Instead, users should consult a health care professional with questions or concerns about results.
It is obvious now that genomics tests need to be supplemented with functional biochemistry tests that are more reflective of characterizing disease states, health conditions, performance and lifestyle. Our deuterobolomics workshop introduces clinical and laboratory methods to measure critical metabolic outputs, organic acid turnover by deuterium and 13C measurements in metabolites from urine, saliva and breath. Ketobolomics and Deuterobolomics tests enhance medical practices with contemporary metabolomics services to include ketogenic dietary interventions and deuterium depleting protocols based on scientific (B) and academic evidence (C) in medical practices. Published studies and de-identified clinical data using stable isotope based methods are discussed and these methods have been reviewed by the FDA as safe and effective tools for metabolic studies to enhance transitional and integrative medicine and clinics.
Laszlo Boros, MD
ABOUT DR. Boros: Dr. Laszlo Boros, MD is currently an Associate Professor of Pediatrics at UCLA and the Co-Director of the Stable Isotope Research Laboratory at Harbor-UCLA Medical Center. His primary focus includes cancer cell metabolism with the use of specifically labeled 13C-glucose tracers and mass spectroscopy. Born and educated in Hungary, Dr. Boros’ medical background includes three years of gastroenterology and pancreatology, focusing on chronic pancreatitis and pancreatic cancer. He spent two years as a visiting scholar in Essen, Germany, studying various animal models of chronic pancreatitis. In 1990, he moved to Columbus, Ohio, where he joined the history-making laboratory of Drs. Zollinger and Ellison, who described hormonal regulatory mechanisms involved in pancreatic cancer growth with a primary emphasis on diagnostics and treatment. In 1995 he became the lead investigator to apply stable isotope technologies to study cancer growth in vitro and in animal models at UCLA. He is an expert in applying metabolic profiling and nanotechnology to further understanding of aggressive growth in kidney and other particularly aggressive cancers. Dr. Boros also participates in clinical research projects targeting population metabolic disorders, such as diabetes and obesity, their link with cancer, and is involved in discovering the underlying mechanisms of rare metabolic disorders arising from genetic mutations affecting vitamin transport.
Dr. Boros’ current collaborators include investigators from international pharmaceutical companies, biotech industry, and prestigious academic institutions, the Food and Drug Administration and National Institutes of Health. Dr. Boros’ mission as a physician scientist is to improve health with the use of targeted tracer fate association studies (TTFA or TTFAS) as standard clinical tools for metabolomics in pre-clinical and clinical development efforts, as well as their therapeutic efficacies in the population.
DISCLOSURE STATEMENT Dr. Boros has indicated that he has no financial relationships with any commercial supporters.
A COMPLIMENTARY TOPIC ARTICLES, COURTESY OF LASZLO BOROS, MD